Battle of the Brains: Rethinking Neurodegenerative Disease Treatment

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
Millions of people around the world are impacted by neurodegenerative diseases— the two most common are Alzheimer’s and Parkinson’s disease. Despite this high prevalence, there are currently only five drugs approved by the FDA to treat Alzheimer's disease. With an increasingly aging population, there is a call to action among scientific experts to diversify neurodegenerative drug discovery through the exploration of new targets.

This panel will hear from executives that are each taking new approaches to treating neurodegenerative disorders. Attendees can expect the session to center around the current challenges in neurodegenerative disease treatment, key findings from past failures and the anticipated next steps in global research.
Moderator
photo
Executive Editor
BioCentury, Inc.
Speakers
photo
Chief Commercial & Strategy Officer
Alkahest
photo
Executive Editor
BioCentury, Inc.
photo
Chief Executive Officer & Chief Scientific Officer
Virscio
photo
Chief executive officer
Cerevance
photo
Chief Executive Officer & Co-founder
Esya Labs